Safety and Effectiveness of Antibody Therapy for Dogs with Splenic Hemangiosarcoma
Hemangiosarcoma is a common, aggressive cancer that arises from the cells that line blood vessels. Common sites of occurrence include the spleen, liver, and the right side of the heart.
The current standard of care for hemangiosarcoma that occurs in the spleen is surgical removal of the spleen followed by chemotherapy. Unfortunately despite surgery and chemotherapy, the disease usually spreads and most dogs succumb to their disease within 6-12 months of diagnosis.
Vascular endothelial growth factor (VEGF) is a growth factor that may contribute to the spread and growth of hemangiosarcoma. In this clinical trial, we will evaluate the safety and effectiveness of an antibody therapy designed to inhibit VEGF and delay or prevent spread of the disease after surgery.
- Dogs that weigh between 10 and 40 kg
- Dogs that are otherwise healthy with a life expectancy of at least 2 months
- Dogs with a histopathological diagnosis of splenic hemangiosarcoma (stage II)
- Dogs that have undergone splenectomy for treatment of splenic hemangiosarcoma
- Intent to complete a 10 week course of doxorubicin chemotherapy
- Dogs with a previous history of:
- Coagulation abnormalities
- Thromboembolic disease
- Congestive heart failure
- Evidence of metastatic disease at screening (pulmonary, cardiac or intra-abdominal)
- Concurrent use of agents including Yunnan Baiyao or Im-Yunity
- Intact females
The study will pay for:
- All visits and clinical and diagnostic tests associated with the clinical trial
- 5 doses of doxorubicin (standard of care chemotherapy)
- Trial drug or placebo administration (given as a single intramuscular injection)
- Treatment of any side effects associated with the trial agent
The study does not pay for initial diagnostic tests or splenectomy.
Please note: This is a randomized, placebo controlled clinical trial enrolling a total of 12 dogs. 6 dogs will receive the trial agent, 6 dogs will receive placebo. Both owners and veterinarians will be blinded.
Dr. Nicola Mason